
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress
On Thursday, Wedbush initiated coverage on Zenas BioPharma, Inc. ZBIO, a clinical-stage global biopharmaceutical company focused on developing therapies for autoimmune disease. Zenas BioPharma started trading on the NASDAQ in September 2024. The company …